INTRODUCTION
MicroRNAs (miRNAs) are short regulatory non-coding RNAs that control gene expression via degradation of target mRNAs and/or inhibition of translation, thereby playing critical roles in dictating the fates of a variety of cells by regulating unique subsets of genes during differentiation (Gammell, 2007) . Hundreds of miRNAs have been identified from many eukaryotic organisms, but specific roles of many of these miRNAs for organ development, homeostasis and metabolism of many organisms have yet to be revealed. Recently, miRNAs have been proposed to play regulatory roles in the process of erythropoiesis. Because a single miRNA can potentially target several hundred genes and conversely, a single gene can bind more than one miRNA (Lewis et al., 2005) , multiple miRNAs may regulate target genes cooperatively for erythropoiesis. The first miRNA identified as being expressed in human erythrocytes was miR-451 (Rathjen et al., 2006) . Later, more signature miRNAs were reported to correlate with common myeloid/erythroid progenitor cell commitment and subsequent maturation. Correlation analysis with umbilical cord blood (CB)-derived CD34+ cells showed that expression of miR-15b, miR-16, miR-22, and miR-185 positively correlated with the appearance of erythroid surface antigens: CD36, CD71 and CD235a, and with hemoglobin synthesis, while induction of miR-28 inversely correlated with expression of these erythroid surface antigens (Choong et al., 2007) . When variation of miRNA expression was assessed in K562 cells, miR-126 was up-regulated while miR-103, miR130a, miR-210, and miR-18b were down-regulated after erythroid cell induction. The same miRNA expression tendency was observed in CD34+ cells isolated from human CB following erythroid induction (Yang et al., 2009) . miRNA profile analysis using mouse erythroid precursors also showed that expression of miR-15b, miR-22, miR-26a, miR-29a, miR-30a-5p, miR-144, miR-292-5p and miR-451 was increased upon erythroid differentiation (Zhan et al., 2007) . miR-451 affects cellular functions such as epithelial cell polarity formation (Tsuchiya et al., 2009) and cancer development (Bandres et al., 2009) . Although microarray analyses for identifying changes in miRNA expression levels during erythropoiesis are informative, these reported results have not been consistent in the literature. miR-142 is involved in hematopoiesis, immune responses, and T cell differentiation (Chen and Lodish, 2005; Ramkissoon et al., 2006; Visone et al., 2009; Wu et al., 2007) . miR-146a is known to suppress metastasis (Edmonds et al., 2009; Li et al., 2010) and more recently it has also been implicated in modulating immune responses (Tsitsiou and Lindsay, 2009; Williams et al., 2008) . miR-451 plays a role in regulating erythropoiesis by repressing negative regulators for erythropoiesis, such as Gata2 (Dore et al., 2008; Kuang et al., 2009; Zhan et al., 2007) . However, it is largely unknown whether these miRNAs are involved in early stages of hematopoiesis. In particular, regulatory roles of these miRNAs in development of human CD34+ hematopoietic cells http://molcells.org from human embryonic stem cells (hESC) and subsequent erythroid differentiation of human CD34+ hematopoietic cells (enriched for stem and progenitor cells) remains to be delineated. In this study we focused particularly on investigating expression changes of miR-142-3p, miR-142-5p, miR-146a, and miR-451 in the hematopoietic system. Here, we report dynamic variations of miR-142-3p, miR-142-5p, miR-146a and miR-451 expression during transition from hESC to CD34+ cells and from hESC derived CD34+ cells to erythroid cells in vitro. Our results suggest that miRNAs may be regulatory targets for possible engagement in erythroid cell commitment.
MATERIALS AND METHODS
Microarray analysis miRNAs profiles in hESCs, mesenchymal stem cells (MSCs) and CB CD34+ cells were analyzed using the Genopal miRNA microarray system (Mitsubishi Rayon Co., Ltd., Yokohama Japan) (Lee et al., 2010) . Chip analysis was repeated at least twice, and hybridization signal intensities were analyzed as described previously (Lee et al., 2010) .
Real time PCR
Gene expression levels were quantified using the ABI 7300 RT-PCR System (Applied Biosytems, USA). Expression levels of mature miRNAs were determined using TaqMan Gene Expression Assays (Applied Biosystems, USA). First strand cDNAs were synthesized from approximately 10 ng total RNAs using superscript II reverse transcriptase (Invitrogen, USA), and cDNAs were amplified for miRNAs by PCR using PCR premix (Gene Bio, Switzerland), Relative quantities of miRNA were calculated using different values between threshold cycles (Ct) of respective miRNAs and RNU6B used as endogenous control. Comparative real-time PCR assays with or without specific primers for miR-142-3p, miR-142-5p, miR-146a, miR-451 were performed in triplicate. Initial reactions were carried out at 95°C for 10 min, followed by additional 40 cycles of reactions at 95°C for 15s and 60°C for 1 min per cycle. Relative expression was calculated using the comparative C t method.
hESC, OP9 cells and co-culture hESC (H9 line) were maintained according to the research protocol of the WiCell Research Institute (USA). H9 colonies were passaged weekly on 10 mg/ml mitomycin C (Sigma, USA) treated mouse embryonic fibroblast feeder cells in DMEM/F-12 basal medium containing 20% serum replacement, 0.1 mM beta-mercaptoethanol, 0.1 mM non-essential amino acids solution, 100 unit/ml penicillin, 100 μg/ml streptomycin, and 4 ng/ml recombinant human FGF-2 (Invitrogen, USA). Differentiated hESC colonies were physically removed from undifferentiated hESCs at purity greater than 90% for each passage. The undifferentiated state of hESC was confirmed based on morphology and loss of OCT-4 expression by immnunocytochemical stain. The OP9 mouse bone marrow stromal cell line was purchased from ATCC, the Global Bioresource Center and maintained according to the manual provided. OP9 cells were grown on gelatin-coated culture dishes for at least five passages in α-modified minimum essential media (α-MEM) (Invitrogen, USA) supplemented with 20% defined fetal bovine serum not heat inactivated (FBS; HyClone Laboratories, USA) for adaptation before the cells were used as feeder cells for hESC differentiation. Hematopoietic differentiation of hESC on OP9 feeder cells was induced in α-MEM containing 10% FBS and 100 μM monothioglycerol (MTG, Sigma, USA) with complete medium change on day 1 followed by a half-medium change on days 4, 6, and 8. Finally on day 10, CD34+ hematopoietic cells were isolated for further differentiation into erythroid cells (Vodyanik and Slukvin, 2007; Vodyanik et al., 2005) .
Isolation and differentiation of CD34+ cells Aggregated cells were harvested from the co-culture and dissociated into single cells by treatment with 0.25% trypsin/EDTA solution (Gibco, USA) for 20-30 min at 37°C and passaged through 70-μm cell strainers (BD Bioscience, USA) after gentle pipetting. CD34+ cells were then isolated by MACS (Miltenyi Biotec, Germany) according to the manufacturer's instructions. Isolated CD34+ cells were induced to differentiate into erythroid lineage cells by culturing for the first 7 days in serum-free Iscove's modified Dulbecco's medium (IMDM, Gibco, USA) supplemented with three cytokines, SCF (Peprotech, USA) at 100 ng/ml, IL-3 (Peprotech, USA) at 5 ng/ml, EPO (STEMCELL Technologies, Canada) at 3 IU/ml, 1% human serum albumin (Sigma, USA), 200 μg/ml iron-saturated human transferrin (Sigma, USA), 50 μg/ml insulin (Sigma, USA), 4 mmol/L L-glutamine (Sigma, USA), 1.6 × 10 4 mol/l monothioglycerol (Sigma, USA) and 1% penicillin-streptomycin solution (Gibco, USA) with a half-medium change twice a week. The cells were continuously differentiated on human bone marrow (BM) derived MSC as feeder cells, by culturing for an additional 7 days in medium but with only erythropoietin (EPO) with a half-medium change every 2-3 days.
